Sanofi

Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

A technologist, wearing purple glove and safety glasses performing structural analysis by HDX-MS, handling samples with precision.

First quarter 2026

Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.

Press Releases


April 24, 2026
Press Release: Sanofi successfully prices 2.3 billion of bond issue

April 24, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

April 23, 2026
Press Release: Q1 2026: double-digit sales and business EPS growth

Upcoming Events

24Mar

2026

BNP Paribas Healthcare Conference – London

Conferences


26Mar

2026

Goldman Sachs 9th Annual Biopharma Innovation Summit – London

Conferences


29Apr

2026

Annual General Meeting 2026

The Sanofi General Meeting will be held on April 29, 2026 at 2:30p.m CET at the Palais des Congrès in Paris.

14:30 - 16:30 CET

Annual general meetings

Discover more

Female scientist in white lab coat and safety equipment working with a tablet at a laboratory workstation with protective hood
Shuang Yang, Scientist, China

2025 20-F

Presenting our 2025 FORM 20-F.

30th Consecutive Year of Dividend Increase

Dr. Yohana Mokiwa has a serious expression, blue shirt and stethoscope, as he speaks with a patient in a pop up clinic
Dr. Yohana Mokiwa speaking with a patient in a pop-up clinic, Dar es Salaam, Tanzania

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00